Please assess the completion status of the following clinical trial:

Trial Title: The Testosterone Trials in Older Men

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men greater than or equal to 65 years old~* Total serum testosterone concentration \< 275 and \< 300 ng/dL at 7 -10 AM at each of two screening visits~Exclusion Criteria:~* Diagnosed prostate cancer, prostatic intraepithelial neoplasia (PIN), prostate nodule or, by the Prostate Cancer Risk Calculator, a \>35% risk of having overall prostate cancer or \>7% risk of having high grade prostate cancer~* Severe lower urinary tract symptoms (score of \> 19) by the International Prostate Symptom Score questionnaire~* Hemoglobin \<10 g/dL or \>16.0 g/dL~* Sleep apnea, diagnosed but untreated~* Alcohol or substance abuse within the past year (based on self report)~* Angina not controlled by treatment~* NYHA class III or IV congestive heart failure~* Myocardial infarction within the previous 3 months before entry~* Stroke within the previous 3 months before entry~* Severe pulmonary disease that precludes physical function tests~* Serum creatinine \>2.2 mg/dL; ALT 3x upper limit of normal; hemoglobin A1c \>8.5%, TSH \> 7.5mIU/L~* Diagnosis or treatment for cancer within the past 3 years, with the exception of nonmelanotic skin cancer~* Body mass index (BMI) \>37 kg/m2~* Mini Mental State Exam (MMSE) Score \<24~* Major psychiatric disorders, including major depression (PHQ-9 score \> 14), mania, hypomania, psychosis, schizophrenia or schizoaffective disorders, that are untreated, unstable, have resulted in hospitalization or medication change within the previous three months, or would result in inability to complete the trial efficacy instruments. Subjects whose disorders have been stable while being treated for more than three months are eligible.~* Use of the following medications within the previous three months:~  * drugs that affect serum testosterone concentration~ * rhGH or megestrol acetate~ * introduction of anti-depressant medication~ * daily use of prednisone for more than two weeks~* Opiate use within the past three months~* Skin conditions at the testosterone gel application site, such as ulcer, erosion, lichenification, inflammation, or crust, or generalized skin conditions such as psoriasis or eczema that might affect testosterone absorption or tolerability of the testosterone gel~* Known skin intolerance to alcohol or allergy to any of the ingredients of testosterone gel~Participants in the T Trial may also enroll in the Cardiovascular and Bone Trials if it is determined that they are eligible based on the specific exclusion criteria.

- Gender: MALE
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- AndroGel® (testosterone gel) (Type: ACTIVE_COMPARATOR): The initial dose of AndroGel will be 5.0 g (containing 50 mg of testosterone) once a day. Participants will apply AndroGel once daily to the shoulders, abdomen or upper arms. The serum testosterone concentration will be measured monthly for the first three months, then at months 6, 9 and 12. If the testosterone concentration is not between 500 and 800 ng/dL at any time point, the dose will be either increased by increments of 1.25-2.5 g/day, up to a maximum of 15 g/day or decreased by increments of 1.25-3.75 ng/day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.
- Placebo gel (Type: PLACEBO_COMPARATOR): Placebo gel is identical to the testosterone gel and is supplied in an identical pump bottle container. It is applied to the shoulders, abdomen or upper arms once a day. Participants will be taught how to apply the gel and they will be provided with written instructions and precautions. This information will be reviewed at each contact and visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).